In a significant governance development for UK deep tech and research commercialisation, Vikas Shah has been appointed to chair the newly established Innovate UK ICURe Advisory Board. The appointment reflects ongoing efforts to strengthen the bridge between academic research and commercial innovation—a priority area for UK startup founders and scale-ups looking to access public funding and research collaboration pathways.

This article unpacks what the appointment means for the UK innovation ecosystem, how ICURe works in practice, and what founders should understand about advisory board structures within Innovate UK's portfolio.

Who Is Vikas Shah and Why Does This Appointment Matter?

Vikas Shah is an established figure in the UK entrepreneurship and innovation landscape, with a background spanning business strategy, venture capital engagement, and public-sector innovation policy. His appointment to chair an advisory board signals a strategic choice by Innovate UK to anchor governance in practitioner expertise rather than purely academic or bureaucratic oversight.

Advisory boards in UK grant-making bodies typically serve three functions:

• Strategic guidance: Advising leadership on programme priorities and market alignment
• Stakeholder credibility: Lending legitimacy to funding decisions and programme design through independent expertise
• Feedback loops: Connecting funded projects and applicants back to decision-makers

Shah's appointment suggests Innovate UK is prioritising input from voices embedded in the commercial startup ecosystem—important for a funding body whose remit includes testing whether research-led projects can genuinely reach market.

Understanding ICURe: What Does It Actually Do?

ICURe (officially part of Innovate UK's innovation support portfolio) exists to support researchers and research-led teams in exploring whether their discoveries have genuine commercial or societal application potential. According to Innovate UK's official researcher guidance, the programme helps researchers test market assumptions, refine business models, and move discoveries closer to commercialisation or real-world deployment.

The distinction matters for founders: ICURe is not a grants programme in the traditional sense. It's a support and exploration mechanism. Teams access advisory support, networking, and potentially small-scale validation funding to prove whether their research-led idea can work outside the lab. This differs from:

• Standard R&D grants (like Innovate UK's Knowledge Transfer Partnerships), which fund development of defined products or services
• SEIS/EIS schemes, which are tax reliefs for private investors backing equity stakes
• Innovate UK Loans, which provide repayable capital for scaling-phase businesses

ICURe participants are typically early-stage, often unfamiliar with commercial processes, and need hand-holding rather than just capital.

The Advisory Board's Role in Innovate UK's Ecosystem

Innovate UK operates under the UK Research and Innovation (UKRI) umbrella and is accountable to Department for Science, Innovation and Technology (DSIT) policy. Within that structure, advisory boards don't set policy or allocate budgets directly. They advise leadership on:

• Whether programme design aligns with market realities and founder needs
• Whether funded projects are selecting genuinely viable innovations
• Emerging gaps in the commercialisation funding landscape
• Stakeholder perception and uptake among target audiences

Shah's chairmanship likely means Innovate UK leadership will have more regular touch-points with someone embedded in founder networks, corporate venture partnerships, and investor conversations. This can translate into better-informed programme design and stronger connection between what researchers apply for and what the commercial ecosystem actually needs.

Timing and Policy Context: Why Now?

The appointment aligns with broader UK innovation policy priorities. The Government's Science and Technology Framework (2022) identified deep tech and research commercialisation as core to UK competitiveness. Several recent initiatives have tried to improve the researcher-to-founder pathway:

• Innovate UK's Biotech Growth Programme: Dedicated support for life sciences founders emerging from academic research
• UK Innovation Visa: Fast-track visa route for founders backed by designated accelerators
• Regional growth hubs: Local support for translating research into commercial ventures

By strengthening ICURe's advisory governance, Innovate UK is signalling that researcher commercialisation remains a priority—and that the current funding and support structures warrant closer scrutiny from commercial insiders like Shah.

What Founders Should Understand About Advising Bodies

For early-stage founders considering ICURe or other Innovate UK support, understanding how advisory boards work is useful context:

Advisory Board Influence Is Real but Bounded

Shah's board will not directly decide which projects get funded or which don't. However, board input shapes the strategic questions leadership asks: Are we funding the right type of innovation? Are we supporting researchers effectively? Are we missing market signals? Over time, this influences eligibility criteria, assessment frameworks, and programme messaging.

Board Members Often Signal Market Trends

Who chairs or sits on an advisory board can telegraph where the funder thinks the market is moving. Shah's appointment may signal that Innovate UK wants to improve its dialogue with commercial venture networks, corporate partners, or founder communities that Shah is embedded in. If you're a founder in Shah's sphere of influence (tech, scale-up strategy, venture-capital-adjacent roles), this might improve your access or the receptiveness of Innovate UK to your sector.

Advisory Boards Create Accountability Pressure

Public advisory board members—especially individuals with credibility in the founder community—create informal accountability. If Innovate UK's funding decisions or programme design diverge too much from what Shah and peers advise, it's harder for leadership to ignore feedback without public reputational cost. This can drive responsiveness to founder concerns.

How This Fits Into Innovate UK's Broader Landscape

Innovate UK offers multiple routes to founders and research-led teams:

• Competitions (project grants): Open calls for R&D funding on specific topics or technologies
• Grants for scale-ups: Larger awards for businesses moving from prototype to market
• Loans and equity: Patient capital via Innovate UK-managed funds
• Support programmes: Non-financial support, including ICURe, for specific cohorts

ICURe sits in the support layer—earlier in the journey than most grant competitions, and focused on validating rather than developing. Shah's advisory role is fundamentally about ensuring that this support tier works well and connects founders effectively to later-stage funding and commercial resources.

Potential Impact on Researcher-to-Founder Transitions

One of the UK innovation ecosystem's historic challenges is the "valley of death"—the gap between research discovery (well-funded through UKRI grants) and early commercial traction (expensive, risky, and poorly served by traditional VC). ICURe is explicitly designed to bridge this gap, but whether it works depends on:

• Whether researchers understand what it offers (not always clearly communicated)
• Whether the support matches researcher needs (business advice can feel irrelevant without peer examples)
• Whether ICURe alumni move successfully into commercial funding (tracked by outcomes, though not always publicised)

Shah's advisory board role, if active, could help pressure Innovate UK to measure and publicise these outcomes—showing founders and researchers that the pathway is real and traceable.

What Founders Can Do Now

If you're a research-led founder or a researcher thinking about commercialisation, the appointment creates no immediate changes to access or eligibility. However, it's worth:

• Checking Innovate UK's current ICURe cohort details at gov.uk/guidance/innovate-uk-support-for-researchers to understand the current application landscape
• Exploring whether your research fits ICURe's scope or whether a traditional grant competition is more appropriate
• Networking within founder communities that Shah engages with—if the advisory board increases those groups' influence on Innovate UK, alignment matters
• Tracking Innovate UK announcements on programme changes or new cohorts, which may reflect advisory board input in coming months

Forward-Looking Analysis: What's Next for Research Commercialisation?

Shah's appointment signals that Innovate UK is investing in governance quality for researcher support. This is positive, but the real test is implementation:

• Will the board meet regularly and publicly report recommendations? Transparency would strengthen founder confidence.
• Will advisory input translate into measurable programme changes? Better tracking of ICURe alumni outcomes, clearer communication to researchers, or adjusted support structures would prove impact.
• Will this model extend to other Innovate UK support programmes? If ICURe's governance strengthens, similar boards for other support routes may follow.

Longer term, UK founder success depends on building credible bridges between research excellence and commercial reality. Shah's appointment is one piece of that puzzle—valuable if it leads to closer dialogue between researchers, commercialisation professionals, and the investor community.

For founders and researchers, the takeaway is straightforward: Innovate UK is signalling that researcher support matters strategically. If you're thinking about commercialising research or bridging from academic discovery to startup, now is a good time to engage with available programmes and track how this governance strengthens the pathway.